EDX Medical Group signs master service agreement with The Royal Marsden

EDX Medical Group plc

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease and infectious diseases, has announced today it has signed a master service agreement with The Royal Marsden NHS Foundation Trust.

Under the terms of the three-year agreement, EDX Medical will, as required, supply services to The Royal Marsden.

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, commented: “I have always had the highest regard for the people and the work they do at The Royal Marsden and have run some significant cancer clinical trials there over the years. I am delighted EDX Medical has now been appointed as a supplier of diagnostic solutions and services to help serve the needs of one of the world’s most eminent cancer hospitals.”

The Board of directors of EDX Medical plc accepts responsibility for this announcement.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

EDX Medical reports 2025 results and advances in cancer diagnostics

EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust.

EDX Medical Group to complete the development of new pneumonia test

EDX Medical will partner with the Intensive Care Unit at Cambridge University Hospitals NHS Foundation Trust to support the further advancement of a highly precise test that identifies the DNA or RNA of the microbes that cause lung infection in critically ill patients. 

EDX Medical and Spire Healthcare sign MOU for diagnostic partnership

EDX Medical Group has partnered with Spire Healthcare to enhance digital diagnostics for cancer and other diseases, promising innovative patient care and improved outcomes.

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care.

EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’

EDX Medical Group plc has secured £3 million by issuing 21.4 million new shares at 14p each, boosting its innovative prostate cancer diagnostic efforts.

EDX Medical Group signs master service agreement with The Royal Marsden

EDX Medical Group has secured a three-year master service agreement with The Royal Marsden NHS Foundation Trust to provide innovative diagnostic solutions for cancer care.

Search

Search